Crossmark

Design and methods of the ‘monitoring outcomes of psychiatric pharmacotherapy’ (MOPHAR) monitoring program – a study protocol

Crossref DOI link: https://doi.org/10.1186/s12913-019-3951-2

Published Online: 2019-02-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Simoons, Mirjam

Ruhé, Henricus G.

van Roon, Eric N.

Schoevers, Robert A.

Bruggeman, Richard

Cath, Daniëlle C.

Muis, Diny

Arends, Johan

Doornbos, Bennard

Mulder, Hans
Funding

Funding for this research was provided by:

MHS Drenthe
License Information

Text and Data Mining valid from 2019-02-14
More Information

Article History

Received: 20 March 2018

Accepted: 7 February 2019

First Online: 14 February 2019

Ethics approval and consent to participate

: The research aspects of MOPHAR were approved by the independent medical ethics committee (RTPO 928, rTPO Leeuwarden, The Netherlands). All participants in MOPHAR research provide written informed consent for use of their data and withdrawal of an extra blood sample for research purposes. Patients that do not provide informed consent for MOPHAR research, will still receive somatic monitoring care from the MOPHAR monitoring program (but their data will not be used nor will an extra blood sample be withdrawn for research purposes).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.